NO742216L - - Google Patents
Info
- Publication number
- NO742216L NO742216L NO742216A NO742216A NO742216L NO 742216 L NO742216 L NO 742216L NO 742216 A NO742216 A NO 742216A NO 742216 A NO742216 A NO 742216A NO 742216 L NO742216 L NO 742216L
- Authority
- NO
- Norway
- Prior art keywords
- factor
- fibrinogen
- cross
- gel
- solution
- Prior art date
Links
- 108010049003 Fibrinogen Proteins 0.000 claims description 73
- 102000008946 Fibrinogen Human genes 0.000 claims description 73
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 70
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 70
- 229940012952 fibrinogen Drugs 0.000 claims description 70
- 239000000243 solution Substances 0.000 claims description 69
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 45
- 108010076282 Factor IX Proteins 0.000 claims description 41
- 210000002381 plasma Anatomy 0.000 claims description 41
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 37
- 229960004222 factor ix Drugs 0.000 claims description 35
- 239000000872 buffer Substances 0.000 claims description 32
- 229920000936 Agarose Polymers 0.000 claims description 31
- 229920002307 Dextran Polymers 0.000 claims description 28
- 229960002086 dextran Drugs 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000010836 blood and blood product Substances 0.000 claims description 21
- 229960000633 dextran sulfate Drugs 0.000 claims description 21
- 229940125691 blood product Drugs 0.000 claims description 20
- 238000010828 elution Methods 0.000 claims description 20
- 239000003463 adsorbent Substances 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 16
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 15
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 15
- 239000003114 blood coagulation factor Substances 0.000 claims description 15
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 13
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- 229920000669 heparin Polymers 0.000 claims description 13
- 229960002897 heparin Drugs 0.000 claims description 13
- 239000001509 sodium citrate Substances 0.000 claims description 13
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 13
- 239000002156 adsorbate Substances 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 108010054218 Factor VIII Proteins 0.000 claims description 9
- 102000001690 Factor VIII Human genes 0.000 claims description 9
- 229940019700 blood coagulation factors Drugs 0.000 claims description 8
- VAANUEHPYNAMQR-UHFFFAOYSA-N 5-amino-2-(4-aminophenyl)cyclohexa-2,4-diene-1,1-disulfonic acid Chemical compound OS(=O)(=O)C1(S(O)(=O)=O)CC(N)=CC=C1C1=CC=C(N)C=C1 VAANUEHPYNAMQR-UHFFFAOYSA-N 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 6
- 229960000301 factor viii Drugs 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 5
- 102000013831 Coagulation factor IX Human genes 0.000 claims description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 5
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 5
- 229940105774 coagulation factor ix Drugs 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
- WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical group NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000004520 water soluble gel Substances 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- 108090000056 Complement factor B Proteins 0.000 claims 1
- 102000003712 Complement factor B Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000012460 protein solution Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 description 123
- 229920002684 Sepharose Polymers 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 28
- 239000012141 concentrate Substances 0.000 description 26
- 239000007858 starting material Substances 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000001179 sorption measurement Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000003756 stirring Methods 0.000 description 16
- 229920005654 Sephadex Polymers 0.000 description 10
- 238000005194 fractionation Methods 0.000 description 10
- 239000012507 Sephadex™ Substances 0.000 description 9
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 239000011149 active material Substances 0.000 description 7
- 230000023555 blood coagulation Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 108010048049 Factor IXa Proteins 0.000 description 6
- 239000007979 citrate buffer Substances 0.000 description 6
- 238000003795 desorption Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 239000004023 fresh frozen plasma Substances 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 208000009292 Hemophilia A Diseases 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000012847 fine chemical Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910021653 sulphate ion Inorganic materials 0.000 description 4
- JCUYNPHEESTECG-UHFFFAOYSA-N 3-amino-6-(4-aminophenyl)benzene-1,2-disulfonic acid Chemical group C1=CC(N)=CC=C1C1=CC=C(N)C(S(O)(=O)=O)=C1S(O)(=O)=O JCUYNPHEESTECG-UHFFFAOYSA-N 0.000 description 3
- 208000031220 Hemophilia Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 229940105778 coagulation factor viii Drugs 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000009429 hemophilia B Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241001146702 Candidatus Entotheonella factor Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ZBZGGZGVFCIXDE-UHFFFAOYSA-N 5-amino-2-(4-aminophenyl)benzenesulfonic acid Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1S(O)(=O)=O ZBZGGZGVFCIXDE-UHFFFAOYSA-N 0.000 description 1
- 229910018626 Al(OH) Inorganic materials 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010035369 Cohn fraction I Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 101000884740 Tachypleus tridentatus Clotting factor B Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000002085 hemarthrosis Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US371491A US3920625A (en) | 1973-06-19 | 1973-06-19 | Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO742216L true NO742216L (da) | 1975-01-13 |
Family
ID=23464186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO742216A NO742216L (da) | 1973-06-19 | 1974-06-18 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US3920625A (da) |
| JP (1) | JPS5035307A (da) |
| AU (1) | AU7020674A (da) |
| DE (1) | DE2429191A1 (da) |
| DK (1) | DK141274B (da) |
| ES (1) | ES427365A1 (da) |
| FI (1) | FI183974A (da) |
| FR (1) | FR2234312B1 (da) |
| GB (1) | GB1460607A (da) |
| IL (1) | IL44828A0 (da) |
| NO (1) | NO742216L (da) |
| SE (1) | SE7407445L (da) |
| ZA (1) | ZA743896B (da) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4170590A (en) * | 1974-12-14 | 1979-10-09 | Biotest-Serum-Institut Gmbh | Ion exchanger treatment of citrate-stabilized plasma |
| DE2459291C3 (de) * | 1974-12-14 | 1981-06-04 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen |
| NZ180199A (en) * | 1976-03-04 | 1978-11-13 | New Zealand Dev Finance | Method of testing for the presence of elevated plasma liprotein concentration |
| NZ180198A (en) * | 1976-03-04 | 1978-11-13 | New Zealand Dev Finance | Cationic ion exchanger with a cross-linked carbohydrate marix |
| JPS52125609A (en) * | 1976-04-09 | 1977-10-21 | Green Cross Corp:The | Purification of agglutination factor viii |
| JPS589824Y2 (ja) * | 1977-07-15 | 1983-02-22 | 本田技研工業株式会社 | 車体フレ−ム装置 |
| US4081432A (en) * | 1977-07-25 | 1978-03-28 | Monsanto Company | Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers |
| US4129648A (en) * | 1977-11-21 | 1978-12-12 | Collier Harry O J | Method for reducing endogenous prostaglandin synthesis |
| SE443293B (sv) * | 1978-01-25 | 1986-02-24 | Blombaeck E G B | Blodfraktionsframstellning |
| DE2902158A1 (de) * | 1979-01-20 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen |
| US4210580A (en) * | 1979-06-19 | 1980-07-01 | David Amrani | Process for separation and isolation of AHF and fibronectin from blood plasma |
| US4278594A (en) * | 1979-06-19 | 1981-07-14 | David Amrani | Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma |
| SE422081B (sv) * | 1979-08-22 | 1982-02-15 | Ird Biomaterial Ab | Sett att pavisa proteolytiska enzymer |
| SE448945B (sv) * | 1979-12-20 | 1987-03-30 | Blombaeck E G B | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
| EP0081482A1 (en) * | 1981-06-18 | 1983-06-22 | E. G. Birger Blombäck | A process in purification and concentration of the factor viii complex |
| US4447416A (en) * | 1982-04-28 | 1984-05-08 | American National Red Cross | Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy |
| US5614500A (en) * | 1983-03-04 | 1997-03-25 | The Scripps Research Institute | Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography |
| US5055557A (en) * | 1983-03-04 | 1991-10-08 | Scripps Clinic & Research Foundation | Ultrapurification of factor IX and other vitamin K-dependent proteins |
| US4515714A (en) * | 1983-03-09 | 1985-05-07 | Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute | Method for purification of hepatitis B virus surface antigen |
| US4627915A (en) * | 1983-04-06 | 1986-12-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Absorbent of autoantibody and immune complexes, adsorbing device and blood purifying apparatus comprising the same |
| AT379310B (de) * | 1983-05-20 | 1985-12-27 | Immuno Ag | Verfahren zur herstellung eines antithrombin iii-heparin- bzw. antithrombin iii-heparinoidkonzentrates |
| GB8403473D0 (en) * | 1984-02-09 | 1984-03-14 | Special Trustees For St Thomas | Purification of factor viii |
| AU571078B2 (en) * | 1984-04-14 | 1988-03-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Purification of filamentous hemagglutinin |
| US5149787A (en) * | 1984-05-22 | 1992-09-22 | The Blood Center Research Foundation | Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing |
| DE3422407A1 (de) * | 1984-06-16 | 1986-03-06 | B. Braun Melsungen Ag, 3508 Melsungen | Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma |
| JPS6147186A (ja) * | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | インフルエンザウイルスの精製方法 |
| JPS6147185A (ja) * | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスの精製方法 |
| JPS6147187A (ja) * | 1984-08-10 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 狂犬病ウイルスの精製方法 |
| JPS6153226A (ja) * | 1984-08-24 | 1986-03-17 | Chemo Sero Therapeut Res Inst | 単純ヘルペスサブユニツトワクチンの精製方法 |
| US5171569A (en) * | 1985-03-15 | 1992-12-15 | National Research Development Corporation | Factor IX preparations uncontaminated by plasma components or pox virus |
| US4675385A (en) * | 1985-03-27 | 1987-06-23 | Alpha Therapeutic Corporation | Isolation of human plasma procoagulant protein factor VIII from biological factors |
| DE3512910A1 (de) * | 1985-04-11 | 1986-10-16 | Behringwerke Ag, 3550 Marburg | Verfahren zur reinigung von plasminogenaktivatoren |
| US4721572A (en) * | 1985-07-12 | 1988-01-26 | Miles Laboratories, Inc. | Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices |
| FR2639958B1 (fr) * | 1988-12-06 | 1992-08-21 | Lille Transfusion Sanguine | Support biologique pour cultures cellulaires constitue de proteines plasmatiques coagulees par la thrombine, son utilisation pour la culture des keratinocytes, leur recuperation et leur transport a des fins d'utilisation therapeutique |
| DE3914869C1 (da) * | 1989-05-05 | 1990-08-09 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
| US4977246A (en) * | 1989-06-06 | 1990-12-11 | Rorer Pharmaceutical Corporation | High recovery process for antihemophilic factor |
| US5110907A (en) * | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
| WO1991013976A1 (en) * | 1990-03-14 | 1991-09-19 | Yamanouchi Pharmaceutical Co., Ltd. | Process for producing purified tissue plasminogen activator or its derivative |
| WO1991016063A1 (en) * | 1990-04-26 | 1991-10-31 | Uab Research Foundation | System for cryoprecipitating fibrinogen |
| AT399818B (de) * | 1992-04-24 | 1995-07-25 | Immuno Ag | Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation |
| US5520885A (en) * | 1993-01-19 | 1996-05-28 | Thermogenesis Corporation | Fibrinogen processing apparatus, method and container |
| US7005510B1 (en) * | 1993-06-23 | 2006-02-28 | Beckman Instruments, Inc. | Recombinant DNase B derived from Streptococcus pyogenes |
| ATE248918T1 (de) * | 1993-06-23 | 2003-09-15 | Beckman Coulter Inc | Rekombinante dnase b aus streptococcus pyogenes |
| US5659017A (en) * | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
| AU1617800A (en) * | 1998-11-12 | 2000-05-29 | Polymer Biosciences, Inc. | Hemostatic polymer useful for rapid blood coagulation and hemostasis |
| DE10325304B3 (de) * | 2003-06-04 | 2005-03-24 | Fresenius Hemocare Adsorber Technology Gmbh | Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin in Blut oder Blutplasma, Verfahren zu seiner Herstellung und seine Verwendung |
| FR2952639B1 (fr) | 2009-11-16 | 2013-08-30 | Lab Francais Du Fractionnement | Procede de purification de facteur b |
| CN107540743A (zh) * | 2017-10-11 | 2018-01-05 | 南岳生物制药有限公司 | 一种双层析法制备人纤维蛋白原的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2543808A (en) * | 1946-12-26 | 1951-03-06 | Parke Davis & Co | Method of preparing fibrinogen |
| US3652530A (en) * | 1967-08-28 | 1972-03-28 | American Nat Red Cross | Antihemophilic factor prepared from blood plasma using polyethylene glycol |
| US3631018A (en) * | 1970-05-01 | 1971-12-28 | Baxter Laboratories Inc | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate |
| US3682881A (en) * | 1970-10-02 | 1972-08-08 | Baxter Laboratories Inc | Fractionation of plasma using glycine and polyethylene glycol |
| SE392038B (sv) * | 1971-09-08 | 1977-03-14 | Kabi Ab | Forfarande for isolering av antitrombin ur blod eller blodprodukter |
| US3803115A (en) * | 1972-05-17 | 1974-04-09 | Baxter Laboratories Inc | Stabilization of ahf using heparin |
-
1973
- 1973-06-19 US US371491A patent/US3920625A/en not_active Expired - Lifetime
-
1974
- 1974-05-14 IL IL44828A patent/IL44828A0/xx unknown
- 1974-06-06 SE SE7407445A patent/SE7407445L/xx not_active Application Discontinuation
- 1974-06-12 JP JP49066975A patent/JPS5035307A/ja active Pending
- 1974-06-17 FI FI1839/74A patent/FI183974A/fi unknown
- 1974-06-18 NO NO742216A patent/NO742216L/no unknown
- 1974-06-18 ZA ZA00743896A patent/ZA743896B/xx unknown
- 1974-06-18 DK DK324374AA patent/DK141274B/da unknown
- 1974-06-18 GB GB2699774A patent/GB1460607A/en not_active Expired
- 1974-06-18 AU AU70206/74A patent/AU7020674A/en not_active Expired
- 1974-06-18 ES ES427365A patent/ES427365A1/es not_active Expired
- 1974-06-18 DE DE2429191A patent/DE2429191A1/de active Pending
- 1974-06-19 FR FR7421281A patent/FR2234312B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DK324374A (da) | 1975-02-10 |
| IL44828A0 (en) | 1974-07-31 |
| ES427365A1 (es) | 1976-07-16 |
| GB1460607A (en) | 1977-01-06 |
| SE7407445L (da) | 1974-12-20 |
| JPS5035307A (da) | 1975-04-04 |
| ZA743896B (en) | 1975-06-25 |
| US3920625A (en) | 1975-11-18 |
| DK141274C (da) | 1980-08-04 |
| DE2429191A1 (de) | 1975-01-16 |
| DK141274B (da) | 1980-02-18 |
| FR2234312A1 (da) | 1975-01-17 |
| AU7020674A (en) | 1975-12-18 |
| FR2234312B1 (da) | 1977-06-24 |
| FI183974A (da) | 1974-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO742216L (da) | ||
| US4022758A (en) | Isolation of coagulation factors I and VIII from biological material | |
| US3842061A (en) | Method for isolation of antithrombin from animal tissue materials by adsorption on sulfated carbohydrate gel | |
| EP0503991B1 (fr) | Procédé de préparation à l'échelle industrielle d'un concentré de facteur von Willebrand humain standardisé, de très haute pureté, approprié à un usage thérapeutique | |
| Hook et al. | Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin | |
| CA1126652A (en) | Antithrombin preparation and process for the production thereof | |
| EP0317376B1 (fr) | Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques | |
| AU648655B2 (en) | Adsorbed cellular fibronectin and process for separating and purifying fibronectins | |
| US5854403A (en) | Method for isolation of highly pure von Willebrand Factor | |
| RU1837880C (ru) | Способ разделени белков крови | |
| CA2024667C (en) | Process for preparing a concentrate of blood coagulation factor viii-von willebrand factor complex from total plasma | |
| NO321139B1 (no) | Farmasoytisk preparat egnet for subkutan, intramuskulaer eller intradermal administrering. | |
| JPH0323528B2 (da) | ||
| JPS59137417A (ja) | 人尿由来コロニ−形成刺激因子及びカリクレインの製造法 | |
| NO138145B (no) | Fremgangsmaate for fremstilling av et enzympreparat | |
| EP0137356B1 (en) | Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism | |
| JP2003518513A (ja) | 血漿プロテアーゼからのフィブリノゲンの分離 | |
| CN109207461B (zh) | 一种凝血因子x激活剂及其制备方法 | |
| US3657416A (en) | Thrombin-like defibrinating enzyme from the venom ancistrodon rhodostoma | |
| US4450104A (en) | Water insoluble gel matrix containing lectin bound to antithrombin | |
| JPH0153650B2 (da) | ||
| US4770877A (en) | Isolation of a high molecular weight aortic endothelial cell growth inhibitor | |
| NO322527B1 (no) | Fremgangsmate for rensing av rekombinant Desmodus rotundus-spyttplasminogenaktivator (rDSPA α 1) fra et biologisk medium. | |
| JPH03218399A (ja) | 尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物 | |
| JPH09286797A (ja) | ヘパリンコファクターｉｉ及びその精製方法 |